论文部分内容阅读
目的为治疗2型糖尿病周围神经病变拓宽临床用药的选择。方法 50例诊断明确的2型糖尿病周围神经病变的患者随机分为治疗组和对照组各25例,在常规综合治疗的基础上,将血糖控制在正常范围内,治疗组给予前列地尔、腺苷钴胺及单唾液酸四己糖神经节苷脂钠(GM1)治疗,对照组仅给予维生素B1及B12治疗,疗程为15 d。观察用药前后临床症状、肌电图神经波幅(AMP)、运动神经传导速度(MCV)及感觉神经传导速度(SCV)的改善情况,同时观察药物不良反应。结果两组治疗后与治疗前比较,肌电图指标均得到显著改善(P<0.01),其中治疗组比对照组改善更显著(P<0.05);治疗组总有效率为92.0%,对照组为48.0%,治疗组临床疗效显著好于对照组(P<0.01)。结论两组用药后临床症状及肌电图指标均改善,但治疗组疗效显著优于对照组,两组用药均安全有效。
The purpose of treatment of type 2 diabetic peripheral neuropathy to broaden the choice of clinical medication. Methods Fifty patients with diagnosed type 2 diabetic peripheral neuropathy were randomly divided into treatment group (n = 25) and control group (n = 25). On the basis of conventional comprehensive treatment, blood glucose was controlled within the normal range. The treatment group was given alprostadil Glycosides and monosialotetrahexosyl ganglioside sodium (GM1) treatment, the control group was given only vitamin B1 and B12 treatment, the course of treatment was 15 d. The clinical symptoms, electromyogram nerve amplitude (AMP), motor nerve conduction velocity (MCV) and sensory nerve conduction velocity (SCV) were observed before and after treatment. Adverse reactions were observed. Results After treatment, the EMG indexes of the two groups were significantly improved (P <0.01), and the treatment group improved more significantly than the control group (P <0.05). The total effective rate of the treatment group was 92.0% Was 48.0%, the clinical efficacy of the treatment group was significantly better than that of the control group (P <0.01). Conclusion The clinical symptoms and EMG indexes of the two groups were improved after treatment, but the treatment group was significantly better than the control group. Both groups were safe and effective.